TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2706175
Drug: Orogastric tube
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orogastric tube followed by 30 ml of sodium citrate 0.3 mol litre‐1
Study: 2706175
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of sodium citrate 0.3 mol litre‐1
Study: 2706175
Drug: Ranitidine 50
Normalized name: ranitidine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 50 mg i.v. before operation, in addition to sodium citrate
Study: 31600833
Drug: bFGF related
Normalized name: bFGF
DrugBank: Basic Fibroblast Growth Factor (DB14131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bFGF related decapeptide solution plus Tacrolimus 0.1% ointment (M + T)
Study: 31600833
Drug: Tacrolimus 0.1%
Normalized name: TACROLIMUS 0.1% OINT,TOP
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus 0.1% ointment (T)
Study: 24914429
Drug: School-based oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based oral health intervention programme with dental hygienists working 4 hours weekly for two years, including fluoride varnish treatments every 6 months.
Study: 24160382
Drug: Intracameral triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracameral triamcinolone acetonide 0.5 mg
Study: 24160382
Drug: Intracameral triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracameral triamcinolone acetonide 1.0 mg
Study: 24160382
Drug: Intracameral triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracameral triamcinolone acetonide 2.0 mg
Study: 17699190
Drug: Very low-protein
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low-protein diet with dietary supplements (study B)
Study: 11369159
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl (median first dose 75 microg/h, median final dose 100 microg/h)
Study: 11369159
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl (for > or =3 months until death)
Study: 9164988
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg zinc gluconate/d for 15 days
Study: 3653532
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg twice daily for 1 week
Study: 29429464
Drug: L-DRD4 genotype
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-DRD4 genotype
Study: 24744272
Drug: Continuous warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous warfarin therapy (group 2)
Study: 24744272
Drug: Warfarin discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin discontinuation (group 1)
Study: 18536787
Drug: Bevacizumab in
Normalized name: bevacizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab in combination with carboplatin and paclitaxel (CbP)
Study: 16202177
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg/d for 6 weeks then 10 mg/d for 6 weeks
Study: 10772527
Drug: Didanosine 50
Normalized name: didanosine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine 50 mg/m2 orally every 12 hr
Study: 6438048
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg enoxacin as a single oral dose
Study: 6438048
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg enoxacin given twice with an interval of 4 hours
Study: 31806612
Drug: Standard visual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard visual scanning therapy (VST)
Study: 24866478
Drug: OC000459 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC000459 25 mg once daily
Study: 24866478
Drug: OC000459 pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC000459 pooled dose groups
Study: 18488223
Drug: Newcastle disease
Normalized name: Newcastle disease virus Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newcastle disease virus (NDV) infected autologous tumour cell vaccine (ATV‐NDV), administered in six doses after liver resection.
Study: 1979900
Drug: Bunazosin hydrochloride
Normalized name: bunazosin hydrochloride
DrugBank: Bunazosin (DB12230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bunazosin hydrochloride 1.5 mg/day for the first week and 3.0 mg/day for two weeks (Group E)
Study: 1979900
Drug: Bethanechol chloride
Normalized name: Bethanechol Chloride
DrugBank: Bethanechol (DB01019)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bethanechol chloride 15 mg three times daily for three weeks (Group B)
Study: 31592824
Drug: Nanosecond pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanosecond pulsed electric field (nsPEF) treatment
Study: 28385353
Drug: Fixed triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed triple therapy (extrafine beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide)
Study: 28385353
Drug: Open triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open triple therapy (BDP/FF plus tiotropium)
Study: 28385353
Drug: Fixed triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed triple therapy
Study: 28385353
Drug: Open triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open triple therapy
Study: 25972054
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with dabigatran-etexilat for 3 weeks followed by DCC
Study: 24229084
Drug: ALA-rich linseed
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-rich linseed oil mixture (17 g/d)
Study: 24229084
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (17 g/d)
Study: 21253725
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of tranexamic acid (TXA) 2000 mg/20 ml
Study: 14709369
Drug: Postprandial remnant-like
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial remnant-like particle (RLP) metabolism in the IR group
Study: 9721802
Drug: High-dose azathioprine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose azathioprine (5 mg/kg/day, adjusted to maintain 6-TGN levels between 100 and 200 pmol/8 x 10(8) RBCs)
Study: 9721802
Drug: Low-dose azathioprine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose azathioprine (3 mg/kg on day 0, then 2 mg/kg/day the first week and 1 mg/kg/day thereafter)
Study: 7988502
Drug: Bromides (BR)
Normalized name: Potassium Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromides (BR) as add‐on therapy
Study: 2574054
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg acrivastine
Study: 789445
Drug: Intravenous Ritodrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Ritodrine
Study: 12927950
Drug: Telithromycin 800
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telithromycin 800 mg/day
Study: 9089471
Drug: GHRH (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (4 bolus injections of 50 micrograms GHRH)
Study: 1584260
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy and radiation therapy (fluorouracil 1000 mg/m² daily for 4 days and cisplatin 75 mg/m² on the first day plus 5000 cGy of radiation)
Study: 1584260
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy alone (6400 cGy)
Study: 2865677
Drug: Patients not
Normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not receiving beta-adrenergic blocking agents
Study: 2865677
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving beta-adrenergic blocking agents
Study: 28166067
Drug: Ultrasound guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided femoral nerve block with 20 ml of 2% lignocaine
Study: 28166067
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl 2 mc/kg
Study: 21830317
Drug: Initial antibiotic
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial antibiotic therapy to eradicate Pseudomonas aeruginosa (Pa) followed by 15 months of intermittent maintenance antibiotics.
Study: 20110697
Drug: MFP dentifrice
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MFP dentifrice (1,450 microg F/g)
Study: 18320252
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 1.8 g/day
Study: 28093999
Drug: Nonprophylaxis users
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonprophylaxis users at baseline on high treatment doses
Study: 19262230
Drug: Candesartan 8‐16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8‐16 mg/day (n = 91)
Study: 19262230
Drug: Enalapril 10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10‐20 mg/day (n = 105)
Study: 16353140
Drug: Pemirolast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemirolast (10 mg) administered orally 2 hours before paclitaxel infusion.
Study: 16353140
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral lactose) administered 2 hours before paclitaxel infusion.
Study: 15342830
Drug: Botulinum neurotoxin
Normalized name: Botulinum neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum neurotoxin type A (BoNT) injections in the submandibular glands
Study: 15342830
Drug: Follow-up assessments
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up assessments after BoNT injections
Study: 9065194
Drug: Mifepristone 600
Normalized name: Mifepristone 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 600 mg followed by Misoprostol 400 micrograms after 48 hours
Study: 31253162
Drug: GLY/eFlow (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLY/eFlow (50 μg GLY delivered by eFlow CS nebulizer)
Study: 31253162
Drug: GLY/DPI (63
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLY/DPI (63 μg GLY delivered by dry powder inhaler)
Study: 31253162
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 50 μg GLY
Study: 16467715
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg twice daily for 16 weeks
Study: 8350289
Drug: Positive coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive coping treatment (short training in conscious use of positive self-statements)
Study: 30165823
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy combining omeprazole, amoxicillin and one of clarithromycin/ciprofloxacin/metronidazole
Study: 30165823
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy combining omeprazole, amoxicillin, ciprofloxacin and doxycycline
Study: 30165823
Drug: Metronidazole based
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole based triple therapy
Study: 30165823
Drug: Ciprofloxacin based
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin based combination therapies
Study: 24281435
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ibuprofen (IBU) at standard doses (10/5/5 mg/kg)
Study: 24281435
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of ibuprofen (IBU) at standard doses (10/5/5 mg/kg)
Study: 24281435
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ibuprofen (IBU)
Study: 24281435
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of ibuprofen (IBU)
Study: 18520598
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg once daily for 11 days)
Study: 11069515
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% ALA lotion
Study: 11069515
Drug: Topical 10%
Normalized name: urea topical 10% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 10% ALA lotion
Study: 11069515
Drug: Topical 20%
Normalized name: urea topical 20% topical foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 20% ALA lotion
Study: 11069515
Drug: Topical ALA
Normalized name: Ala-Cort Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ALA lotion (5%, 10%, 20%) vs. Vehicle lotion
Study: 22970150
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri DSM 17938 (5 × 10^8 CFUs daily for 2 months)
Study: 20950882
Drug: High dose-rate
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose-rate brachytherapy (HDRBT) alone
Study: 6927281
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of moxalactam and cefazolin (10 mg/kg)
Study: 6927281
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of moxalactam and cefazolin (10 mg/kg)
Study: 25546368
Drug: Twice‐weekly prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice‐weekly prophylaxis (20‐30 IU kg(‐1))
Study: 25546368
Drug: 3‐times‐weekly prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐times‐weekly prophylaxis (30‐40 IU kg(‐1))
Study: 25546368
Drug: Combined prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined prophylaxis (twice‐weekly and 3‐times‐weekly)
Study: 24203649
Drug: Radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine therapy (RIT)
Study: 24203649
Drug: Antithyroid drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drug therapy (ATD)
Study: 19375093
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg esreboxetine
Study: 17302567
Drug: Doxazosin gastrointestinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin gastrointestinal therapeutic system (4 mg doxazosin)
Study: 9437205
Drug: Oral arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral arginine HCl (8.4 g/d) administered to HC subjects for 2 weeks
Study: 9437205
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment in HC subjects
Study: 27669680
Drug: Lubiprostone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone (8 μg b.d.)
Study: 23433435
Drug: Cisplatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (40 mg/m² weekly for 6 weeks)
Study: 23433435
Drug: Cetuximab (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (250 mg/m² weekly with a loading dose of 400 mg/m² for 6 weeks)
Study: 23433435
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of median (89)Zr-Cetuximab uptake and biological markers with treatment specific outcome
Study: 18971537
Drug: Losartan (25-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (25-100 mg)
Study: 10946911
Drug: Pegvisomant 30
Normalized name: pegvisomant 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvisomant 30 mg or 80 mg weekly for 6 weeks
Study: 10946911
Drug: Pegvisomant 10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvisomant 10‐20 mg/d for 12 weeks
Study: 7192153
Drug: Acetaminophen (paracetamol)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (paracetamol) 1000 mg
Study: 7192153
Drug: Hydrocodone 10
Normalized name: HYDROCODONE 10/PPA 25MG/5ML SYRUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone 10 mg
Study: 7192153
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acetaminophen plus hydrocodone
Study: 16600222
Drug: Oral carnitine
Normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral carnitine (2,000 mg L-carnitine and 1,000 mg L-acetyl-carnitine per day)
Study: 12686329
Drug: unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: unfractionated heparin (UFH)
Study: 10599875
Drug: Intrathecal baclofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal baclofen (ITB) at doses of 25, 50, and 75 microg
Study: 7295193
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment (fat-controlled, low cholesterol diet)
Study: 29773947
Drug: BFF MDI
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BFF MDI 160/9.6 μg
Study: 29773947
Drug: BFF MDI
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BFF MDI 80/9.6 μg
Study: 29773947
Drug: BD MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BD MDI 320 μg
Study: 24386491
Drug: Neuromuscular electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromuscular electrical stimulation (NMES) of the quadriceps, ideally daily sessions of 30 minutes, minimum three times weekly
Study: 20577660
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal system (BTDS) 5 microg/h to 20 microg/h
Study: 15954961
Drug: Ephedrine (210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (210 microg kg(‐1)) + Rocuronium (0.04 mg kg(‐1)) with 3-min priming interval
Study: 15954961
Drug: Rocuronium (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (0.04 mg kg(‐1)) with 3-min sham priming
Study: 15954961
Drug: Rocuronium (0.44
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (0.44 mg kg(‐1)) with 3-min sham priming
Study: 15954961
Drug: Rocuronium (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (0.04 mg kg(‐1)) with 3-min priming and normal saline
Study: 10485352
Drug: MF59-adjuvanted subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted subunit virus vaccine (SU/MF59)
Study: 6109059
Drug: Hycanthone 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hycanthone 0.75 mg/kg
Study: 6109059
Drug: Hycanthone 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hycanthone 1.5 mg/kg
Study: 26209535
Drug: Daily low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily low-dose hCG (125 IU) for luteal phase support after GnRHa trigger, initiated on stimulation day 2 or day 6.
Study: 26209535
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group followed a standard antagonist protocol without hCG supplementation.
Study: 19939650
Drug: Enriched dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enriched dairy product (0.6 L/day) for 5 months
Study: 19939650
Drug: Standard whole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard whole milk (0.6 L/day) for 5 months
Study: 19729323
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 300 mg day(-1) for 15 days (Group III)
Study: 19729323
Drug: Varicose veins
Normalized name: DIMETHICONE 30 mg in 1 mL TOPICAL CREAM [AnYi Beauty Varicose Veins Cream]
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varicose veins (Group II, no drug treatment)
Study: 17825692
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate 880 microg IN qSh for 10 doses
Study: 11260238
Drug: 10% diethylenetriaminepentaacetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% diethylenetriaminepentaacetic acid (DTPA) cream
Study: 8312583
Drug: Tamoxifen adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen adjuvant therapy
Study: 23252007
Drug: Intravenous hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydration before and after coronary angiography or angioplasty (Group A, n=40)
Study: 23252007
Drug: Oral tap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tap water before and after the procedures (Group B, n=40)
Study: 20422945
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of 50 mg itopride HCl
Study: 20422945
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of 50 mg itopride HCl